Functional ingredients from IminoTech and Gateway Health Alliances will be distributed by Vivatis Pharma in Europe

In a recent news release, affiliated companies IminoTech and Gateway Health Alliances announced that Vivatis Pharma would be distributing their functional ingredients in Europe. With the new partnership, selected joint health and weight management ingredients available to be used in functional foods, beverages, and dietary supplements will be represented and distributed by Vitatis Pharma.

Functional ingredient supplier and developer Vivatis Pharma serves manufacturers, brand owners, and distributors across Europe. Its portfolio includes raw materials, functional food additives, and private-label product solutions.

“We are excited to partner with Vivatis Pharma to expand access to our clinically supported ingredients in the European market,” stated Shil Kothari, chief executive officer of IminoTech and President of Gateway Health Alliances, in the press release. “Vivatis brings strong marketing and technical expertise to help manufacturers develop innovative wellness solutions.”

The first two products involved in the new partnership are Q-actin from Imino and IGOB131 from Gateway Health Alliances. Standardized to more than 1% ido-BR1, Q-actin is a cucumber (Cucumis sativus) extract intended for joint flexibility and support. A placebo-controlled study published in Current Rheumatology Reviews in 2023¹ found dose-dependent reduction in pain-related parameters including joint function and performance of daily tasks. The 180-day trial was completed by 91 patients with knee osteoarthritis who were given a 20 mg dose of Q-Actin, a 100 mg dose, or a placebo. A progressive reduction in pain for both Q-Actin doses was observed.

An extract of Irvingia gabonensis (African mango), IGOB131 is intended to support healthy metabolism and weight management through enzyme and hormone modulations. A randomized, double-blind, placebo-controlled parallel group study published in Functional Foods in Health and Disease in 2020² demonstrated significant reductions in body fat ratio, triglycerides, body weight, BMI, waist circumference, hip circumference, and visceral fat in the supplement group compared with the placebo group. The 12-week trial involved 32 participants.

References

1. Nash, RJ.; Mafongang, A.; Singh, H.; Singwe-Ngandeu, M.; Penkova, YB.; Kaur, T.; Akbar, J. Standardised ido-BR1 Cucumber Extract Improved Parameters Linked to Moderate Osteoarthritis in a Placebo-controlled Study, Current Rheumatology Reviews. 2023, 19(3). DOI: 10.2174/1573397119666230206105703.
2. Shiojimi, Y.; Takahashi, M.; Kikuchi, M.; Akanuma, M. Effect of ellagic acid on body fat and triglyceride reduction in healthy overweight volunteers: a randomized, double-blind, placebo-controlled parallel group study, Functional Foods in Health and Disease. 2020, 10(4). DOI: 10.31989/ffhd.v10i4.702.